Semaglutide and tirzepatide telehealth access, compounded GLP-1 program pricing, refund terms, and weight loss medication ...

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NYSE: NVO) did during the GLP-1 ...

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective approved obesity drugs. This practice raises practical questions.

Novo Nordisk said April 23 it plans to seek expanded FDA approval for its Ozempic pill in the second half of 2026, which would make the drug the first oral GLP-1 approved for children and adolescents ...

Novo Nordisk A/S NVO reported positive topline results from its late-stage PIONEER TEENS trial, showing that oral semaglutide ...

Him & Hers announced Thursday that eligible users can now access the full r | Providers can now send prescriptions of Eli ...

Armed with new phase 3 data, Novo Nordisk has said it will file for approval of oral formulations of its GLP-1 agonist ...

Children and adolescents with type 2 diabetes had an improvement in HbA1c at 26 weeks with a once-daily oral GLP-1, according ...

GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

Stock index futures fell Thursday, a day after Wall Street edged higher with both the Nasdaq and S&P 500 touching record ...

Amazon offers weight loss drug pricing and delivery to about 3,000 cities, including Seattle, and plans on expanding to 4,500 ...